714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Enlituo® Colorectal Cancer	Taizhou Mabtech Pharmaceutical Co.,Ltd	P3	NR ()
gpa33-cc;177lu-smartd2 Colorectal Cancer	SmartNuclide Biopharma	Early P1	NR ()
Inv-8989 Colorectal Cancer	Shenzhen Ionova Life Sciences Co., Ltd.	P1/2	NR ()
jmt203 Colorectal Cancer	Shanghai JMT-Bio Inc.	P1/2	NR ()
Kst-6051 Colorectal Cancer	Kestrel Therapeutics, Inc.	P1	NR ()
Mdna11 Colorectal Cancer	Medicenna Therapeutics, Inc.	P1/2	NR ()
Medi5257 Colorectal Cancer	Assistance Publique - Hôpitaux de Paris	P2	NR ()
Ptemizumab Colorectal Cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1	NR ()
s-531011 Colorectal Cancer	National Cancer Center Hospital East	P1/2	NR ()
TQB2922 Colorectal Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1/2	NR ()
Traditional Chinese Medicine Tdx105 Colorectal Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	NR ()
Wef-001 Colorectal Cancer	Auricula Biosciences Inc.	P1/2	NR ()
Ymn-136 Vaccine Colorectal Cancer	West China Hospital	P1	NR ()
Ymn-A02 Colorectal Cancer	West China Hospital	P1	NR ()

Showing 701 to 714 of 714 assets

PreviousPage 15 of 15Next